Thyroid-stimulating hormone (TSH) levels may be associated with the risk of nonalcoholic fatty liver disease (NAFLD) and its progression into nonalcoholic steatohepatitis (NASH), a recent meta-analysis has shown.
Combination therapy with the NS5A inhibitor ledipasvir and NS5B inhibitor sofosbuvir appears to be highly effective in the management of chronic hepatitis C virus genotype 1 infection, yielding a sustained virologic response of >90 percent without increasing the incidence of serious adverse events, according to data from a real-world Japanese cohort.
The fluoroquinolone norfloxacin does not appear to reduce 6-month mortality in patients with advanced cirrhosis, according to a study. However, the drug confers survival benefits among those with low ascites fluid protein concentrations.
In patients with chronic hepatitis B (CHB) infections on nucleos(t)ide analogue (NA) treatment, normal on-treatment alanine aminotransferase levels are associated with lower risks of hepatic events, a recent study has shown.
Monoprophylaxis with entecavir (ETV) or tenofovir (TDF) following a 6-month combination therapy regimen of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues can prevent recurrence of hepatitis B virus (HBV) infection, a recent study has shown.
High-risk patients may benefit from a protective effect of statins against hepatocellular carcinoma, a recent study suggests. This effect appears to be greater in patients with diabetes mellitus or liver cirrhosis.